MedTrace Logo

Lacripep for Corneal Wound Healing Study

NCT06854393 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-03-25

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).

Conditions

  • Corneal Epithelial Wound Healing

Interventions

DRUG

0.00025% Lacripep ophthalmic solution and Placebo

Participant will receive Lacripep in one eye and placebo in the other eye at the same time.

Sponsors & Collaborators

  • TearSolutions, Inc.

    collaborator INDUSTRY

  • Walter Reed National Military Medical Center

    collaborator FED

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    lead OTHER

Principal Investigators

  • Zachary P Skurski, DO · Alexander T. Augusta Military Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-23
Primary Completion
2027-06-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06854393 on ClinicalTrials.gov